Inhibrx Biosciences, Inc. (INBX): M&A transaction — Inhibrx Biosciences completes spin-off from RemainCo, lists 14.5M shares outstanding

Inhibrx Biosciences, Inc.

Completed spin-off on May 29, 2024; 92% of Inhibrx Biosciences shares distributed to RemainCo shareholders at 1:4 ratio.
As of May 30, 2024, 14,475,904 shares of common stock outstanding post-distribution.
Issued warrants for up to 991,849 shares at $0.0001 exercise price, no expiration; also issued 1,838 shares to Oxford Finance.
Entered registration rights agreement requiring filing of resale registration statement within 10 business days.
Entered employment agreements with CEO Lappe ($695,250 base), CFO Eckelman ($535,600), and CAO Deck ($460,100) with 12-month severance.

item 1.01 item 3.02 item 3.03 item 5.03 item 5.01 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Inhibrx Biosciences, Inc. underwent a change of control involving Inhibrx, Inc. (closed 2024-05-29).

Action: change of control
Counterparty: Inhibrx, Inc.
Closing: 2024-05-29

Exact text from the filing

On May 29, 2024, Inhibrx, Inc., a Delaware corporation (“RemainCo”), completed the distribution of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc., a Delaware corporation (the “Company”), to holders of shares of RemainCo’s common stock as of the distribution record date of May 17, 2024, on a pro rata basis (the “Distribution”), at a ratio of one share of the Company’s common stock for every four shares of RemainCo’s issued and outstanding common stock held on the distribution record date.

View on SEC.gov

Browse all m&a transactions →

Inhibrx Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-066645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.